跳至主要内容
临床试验/NCT04591600
NCT04591600已完成1 期

Controlled Randomized Clinical Trial on Using Ivermectin With Doxycycline for Treating COVID-19 Patients in Baghdad, Iraq

Alkarkh Health Directorate-Baghdad1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2020年7月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
140
试验地点
1
主要终点
Mortality rate

研究概览

简要总结

A randomized controlled trial on using Ivermectin and doxycycline to treat mild-moderate outpatients, severe, and critical inpatients of Coronavirus disease 19 (COVID-19) along with standard of care. Seventy Iraqi COVID-19 patients received Ivermectin and Doxycycline plus standard of care versus seventy Iraqi COVID-19 patients received standard of care only. .

详细描述

Objectives: COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try old re-purposed drugs on COVID-19. Methods: Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11 critical patients) treated with 200ug/kg PO of Ivermectin per day for 2 days along with 100mg PO doxycycline twice per day for 5-10 days plus standard therapy; the second arm is 70 COVID-19 patients (48 mild-moderate and 22 severe and zero critical patients) on standard therapy. The time to recovery, the progression of the disease, and the mortality rate were the outcome-assessing parameters.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
16 Years 至 86 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • COVID-19 patients at any stage of this disease

排除标准

  • Patients of allergic history to Ivermectin or to doxycyline

研究组 & 干预措施

Ivermectin-Doxycycline

Experimental

Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.

干预措施: Ivermectin and Doxycyline (Drug)

Ivermectin-Doxycycline

Experimental

Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard of care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.

干预措施: Standard of care (Drug)

Control

Active Comparator

Control group: The patients in this group received only standard care which included all or some of the following, according to the clinical condition of each patient.

干预措施: Standard of care (Drug)

结局指标

主要结局

Mortality rate

时间窗: Up to 8 weeks

The effect of the experimental drugs to reduce the mortality rate (death rate) of treated patients

Rate of progression disease

时间窗: up to 8 weeks

rate of patients under treatment who undergo progression of disease to a more advanced stage

次要结局

  • Time to recovery(Up to 8 weeks)

研究者

发起方
Alkarkh Health Directorate-Baghdad
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Ahmed Sahib Abdulamir

M.B.Ch.,B., Phd Virology, Professor

Alkarkh Health Directorate-Baghdad

研究点 (1)

Loading locations...

相似试验